Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2003;326:1196-1198 (31 May), doi:10.1136/bmj.326.7400.1196
Elizabeth Wager, publications consultant1
1 Sideview, Princes Risborough HP27 9DE liz@sideview.demon.co.uk
Interactions between doctors and drug companies can lead to ethical dilemmas. This article gives an overview of the guidance and codes of practice that aim to regulate the relationship
| The first 150 words of the full text of this article appear below. |
Like the porcupine's quills, drug companies' interactions with doctors are numerous and can be harmful if approached the wrong way. (Lewis and colleagues used the analogy of dancing with porcupines to describe university-industry relations,1 and I liked it so much I have appropriated it.) I have aimed to highlight the major rules and guidelines relating to interactions between doctors and drug companies, but this is not an exhaustive survey.
|
|
SUE SHARPLES
|
Codes of conduct for pharmaceutical companies developed by industry
organisations tend to be voluntary but are often backed up by complaints
procedures. Many countries with major pharmaceutical sectors have national
codes, such as those of the Association of the British Pharmaceutical Industry
(ABPI),2 Medicines
Australia,3 and the
Pharmaceutical Research and Manufacturers of
America.4 These
usually concentrate on drug companies' marketing activitiesmost
prohibit companies from giving doctors inducements to prescribe their products
in the form of payments, lavish gifts, or
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses